Arbutus Biopharma (ABUS) Change in Cash (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Change in Cash for 14 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Cash rose 663.81% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 121.91% YoY) and the FY2025 annual result came in at -$18.3 million, down 282.4% from the prior year.
• Change in Cash climbed to $5.7 million in Q1 2026 per ABUS's latest filing, from -$4.4 million in the prior quarter.
• Over the last five years, Change in Cash for ABUS reached as high as $19.7 million in Q2 2024 and fell as low as -$34.0 million in Q2 2022.
• A 5-year average of -$5.0 million and a median of $336000.0 in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash sank 220.11% — and 2026, when it jumped 663.81%.
• Year by year, Change in Cash stood at $6.8 million in 2022, then grew by 29.27% to $8.8 million in 2023, then slumped by 48.78% to $4.5 million in 2024, then plunged by 198.13% to -$4.4 million in 2025, then soared by 229.5% to $5.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $5.7 million, -$4.4 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.